April 24, 2021
1 min read
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact [email protected].
Back to Healio
According to a press release, Lamassu Pharma announced that the development of its lead therapeutic compound, RABI-767, could meet the unmet clinical need for the treatment of patients with pancreatitis.
RABI-767 is a novel low molecular weight lipase inhibitor that is injected directly into the pancreas. In preclinical studies, it decreased the breakdown or release of unsaturated fats and saturated fats during acute attacks of pancreatitis. The value of this therapeutic has been underscored by recent research by the Mayo Clinic which found that the rapid breakdown of unsaturated fat can worsen the course of severe acute pancreatitis, resulting in increased toxicity, organ failure, and death.
Patients with acute pancreatitis who develop COVID-19 may experience increased inflammation, putting them at a higher risk of further complications. The development of RABI-767 can help understand the role of fatty acids in the virus.
“We accelerated development by tailoring business for science – not the other way around. When we get approval, our drug RABI-767 will be the first and only drug given by intraperitoneal injection to advance science and to preserve science. ” Mechanism of action that ensures the effectiveness of the drug ” Gabi Hanna, MD, Lamassu Pharma CEO said in the press release.
Lamassu expects clinical trials to be approved in the next few months and is closely monitoring the COVID-19 variants to tailor future research specifically to treating patients with COVID-19.
ADD SUBJECT TO EMAIL ALARMS
Receive an email when new articles are published
Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe
We could not process your request. Please try again later. If you continue to have this problem, please contact [email protected].
Back to Healio
